+1.3%
FSLR vs GSK
+31.2%
-30.0%
-37.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.4% | -1.9% | +0.5% | -1.5% |
| 7D | 0.0% | -1.8% | +1.8% | -0.1% |
| 30D | -13.7% | -2.2% | -11.5% | -13.6% |
| 3M | -35.1% | -1.8% | -33.3% | -35.0% |
| 6M | +3.6% | -10.6% | +14.2% | +3.3% |
| YTD | -21.7% | +4.4% | -26.2% | -19.7% |
| 1Y | +1.3% | +30.4% | -29.1% | +6.7% |
| All | +1.3% | +31.2% | -30.0% | +6.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling